Medindia
Medindia LOGIN REGISTER
Advertisement

LaVoie Group Adds Two New Companies to Its Life Science Client Roster

Monday, November 19, 2007 General News
Advertisement
SALEM, Mass., Nov. 19 LaVoie Group, a life sciencesfocused, corporate, investor and public relations firm, today announced thatit has been selected as agency of record by Agile Therapeutics, of Princeton,NJ, and The GI Company, of Framingham, MA.
Advertisement

Donna LaVoie, President and CEO, commented, "LaVoie Group is engaged inproviding strategic communications counsel and tactical execution to theseexciting companies as they accelerate interactions with the venture capital,biopharmaceutical and professional medical communities. The addition of theseclients underscores the increasingly diverse nature of our life sciencesroster."
Advertisement

Ms. LaVoie continued, "Agile Therapeutics is a specialty pharmaceuticalcompany addressing unmet needs in women's healthcare, while The GI Companyspecializes in developing drugs for gastrointestinal and related diseases.Both are poised to make an impact in their respective therapeutic areas."

About Agile Therapeutics

Agile Therapeutics is a specialty pharmaceutical company focused on thedevelopment of innovative women's healthcare products. The company's late-stage products are driven by a market need for a convenient and reliable low-dose contraceptive patch. Agile is capitalizing on its executive team'sproven expertise in transdermal technology, drug development, and fertilitymanagement to build a pipeline of women's health products through lineextensions and/or in-licensing. For more information, visitwww.agiletherapeutics.com.

About The GI Company

The GI Company is a clinical-stage biotechnology company highlyspecialized at developing drugs to treat gastrointestinal and relateddiseases. The company's lead clinical candidate, Intestinal Trefoil Factor(ITF), is being developed for the treatment of oral mucositis, a common,debilitating complication resulting from high-dose chemotherapy and/orradiotherapy. Phase II clinical results are expected to be released in the1st half of 2008. The GI Company also has pre-clinical development programsin enteritis/proctitis, inflammatory bowel disease, erosive gastroesophagealreflux disease, peptic ulcer disease and gastrointestinal motility disorders,as well as clinical programs in erosive gastritis (NSAID induced), ulcerativecolitis and corneal wound healing. For more information, visitwww.thegicompany.com.

About LaVoie Group

LaVoie Group provides senior level strategic counsel and tacticalimplementation of public, investor and corporate communications programsdesigned to properly position, create visibility and drive value for eachclient. Our clients range from private start-ups to industry leaders in lifesciences. For more information, visit www.lavoiegroup.com.

SOURCE LaVoie Group
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close